Adage Capital Partners
CORT icon

Adage Capital Partners’s Corcept Therapeutics CORT Stock Holding History

Adage Capital Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-96,172
Closed -$7.06M – 906
2025
Q2 		$7.06M Buy
+96,172
New +$6.97M 0.01% 669
2013
Q3 		– Sell
-655,984
Closed -$1.14M – 691
2013
Q2 		$1.14M Buy
+655,984
New +$1.18M ﹤0.01% 658

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Adage Capital Partners's CORT Position: Q3 2025 in Review

Adage Capital Partners sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 96,172 shares — an estimated $7.06M sold.

Adage Capital Partners first reported a position in CORT in Q2 2013 and held it in 2 quarters. The position peaked at $7.06M in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Adage Capital Partners reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 96,172 Corcept Therapeutics shares in Q3 2025, an estimated $7.06M.
  • Adage Capital Partners first reported a position in Corcept Therapeutics in Q2 2013 and held it in 2 quarters.
  • Adage Capital Partners's Corcept Therapeutics position peaked at $7.06M in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.